Download PDFPDF
Ocular adnexal marginal zone B-cell lymphoma: the low-dose dilemma
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Dilemma of Ultra-low dose vs Low-dose Radiation Therapy for Ocular Adnexal Lymphomas: The prospective trial has been underway
    • Bita Esmaeli, MD, FACS Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, M. D. Anderson Cancer Center, Houston, Texas, USA
    • Other Contributors:
      • Chelsea Pinnix, MD
      • Tine Gadegaard Hindso, MD
      • Steffen Heegaard, MD, DMSci

    To the Editor:
    We herein respond to the letter written by Camus et al raising the issue of “ultra-low” dose radiation therapy (4 Gy) vs. the “standard low-dose” radiation therapy (24-30 Gy) for lymphomas of the orbit, eyelid, and conjunctiva, also referred to as “ocular adnexal lymphoma” (OAL). First off, it is important to point out that the goals of the retrospective multicenter general review of marginal zone lymphoma coordinated by Professor Steffen Heegaard in Denmark which also included some of our patients from M. D. Anderson was not to compare the efficacy of various treatment strategies.(1) Indeed it is challenging to draw practice altering conclusions from a retrospective multi-center study given the usual limitations, most notably the variation in staging and treatment approaches across various continents as noted by Camus et al.

    However, we agree with Camus et al that our encouraging preliminary observations in 22 patients with OAL treated with ultra-low dose radiation therapy (4Gy) suggested a very good response rate (100% ORR:86% CR, 14%% PR) for B-cell orbital and ocular adnexal lymphomas;(2) as such we started a prospective trial of ultra-low dose radiation for ocular adnexal lymphoma patients at MD Anderson Cancer Center soon thereafter ( identifier NCT02494700)The study aims to evaluate the efficacy of response adapted radiation therapy for this patient population, whereby all patients are treated to an initial 4 Gy in...

    Show More
    Conflict of Interest:
    None declared.